Multiple endocrine neoplasia syndrome type 2 (MEN2) 6
Older adults, those with cardiac conditions, and patients on insulin or other glucose-lowering agents may benefit from slower titration or plateau at lower doses to avoid hypoglycemia and cardiovascular complications
Despite a similar proportion of subjects reporting AEs in all groups, a higher number of AEs were reported with OW s.c
A 2025 systematic review of four randomized controlled trials involving 27,617 participants showed that semaglutide reduces MACE by 19% (relative risk 0.81, 95% CI 0.74-0.88), with additional benefits for cardiovascular death and nonfatal heart attack
Real Patient Stories Ozempic and similar medications have empowered thousands of patients to take control of their health and their bodies
Available from: Accessed June 1, 2025